Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.40 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.39 |
| ▸ | CHRNG | P07510 | 1/20 | 0.39 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.39 |
| ▸ | CHRND | Q07001 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22260405 | 0.84 | KDM4E (0.47) | MAPTHSD17B10TSHREPHX1EPHX2 | |
| SCHEMBL15685088 | 0.83 | EPHX1 (0.52) | EPHX1EPHX2PAOX | |
| SCHEMBL6287295 | 0.82 | MAPT (0.44) | MAPTHSD17B10TSHREPHX1EPHX2 | |
| SCHEMBL6287189 | 0.82 | MAPT (0.44) | MAPTHSD17B10TSHREPHX1EPHX2 | |
| SCHEMBL6287617 | 0.82 | MAPT (0.44) | MAPTHSD17B10TSHREPHX1EPHX2 | |
| SCHEMBL1014742 | 0.81 | PAOX (0.57) | EPHX1EPHX2PAOX | |
| SCHEMBL21172210 | 0.81 | MEN1 (0.55) | TSHREPHX2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL15185814 | 0.80 | PAOX (0.62) | TSHRCHRNA1CHRNGCHRNB1CHRND | |
| SCHEMBL18670747 | 0.80 | PAOX (0.62) | TSHRCHRNA1CHRNGCHRNB1CHRND | |
| SCHEMBL28419176 | 0.80 | PAOX (0.61) | EPHX1EPHX2PAOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139456-B2 | Chelating compounds and immobilized tethered chelators | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139456-B2 | Chelating compounds and immobilized tethered chelators | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2015-09-22 | — | — | US | disclosed |
| US-20120061325-A1 | CHELATING COMPOUNDS AND IMMOBILIZED TETHERED CHELATORS | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2012-03-15 | — | — | US | disclosed |
| US-20120061325-A1 | CHELATING COMPOUNDS AND IMMOBILIZED TETHERED CHELATORS | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120061325-A1 | CHELATING COMPOUNDS AND IMMOBILIZED TETHERED CHELATORS | BTD, TTPA, SLC39A7 | MAPT 2716/4885HSD17B10 4580/4885TSHR 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.